| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update |
Company has continued to advance its previously announced plan to obtain FDA approval for two new drugs and to develop a network of clinics focused on neuroplastic therapies to treat severe and suicidal depression, PTSD, and related conditions. Clinic acquisition financing is at the HOPE Therapeutics level and non-dilutive to NRXP shareholders In January 2025 completed the third tranche of a convertible note offering and registered direct equity offering to an institutional investor on favorable terms to the Company; expected to provide sufficient cash to support operations through the end of 2025. |
prnewswire.com |
2025-05-15 20:03:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions |
Term sheet with Universal Capital, LLC to fund HOPE Therapeutics clinic acquisition strategy Funding tied to already-announced acquisitions, with additional tranches contemplated for further growth, subject to standard due diligence Together with previously announced term sheet with a strategic investor, HOPE funding of $10.3 million is planned in the near term MIAMI , May 15, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a multi-site clinical care delivery organization and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a term sheet with Universal Capital, LLC ("Universal") to provide $7.8 million in acquisition capital to initiate HOPE's planned national rollup of interventional psychiatry clinics, commencing with previously-announced acquisitions of Dura Medical, Kadima, and NeuroSpa. Together with proceeds of a previously announced strategic investment, this financing is anticipated to provide $10.3 million in acquisition capital. |
prnewswire.com |
2025-05-15 14:15:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals (NASDAQ:NRXP) Announce Signing of Definitive Agreement to Purchase Kadima Neuropsychiatry Institute; Foundational Acquisition for the HOPE Network of Interventional Psychiatry Clinics |
Kadima Neuropsychiatry Institute in La Jolla, CA expected to serve as clinical model for Hope treatment offerings nationwide Kadima is a leading investigative site for CNS and psychedelic research, having served as the lead site in nearly all major trials in this space Dr. David Feifel, a nationally recognized pioneer in interventional psychiatry to join HOPE as Chief Medical Innovation Officer upon closing Acquisition expected to be accretive to revenue and EBITDA for NRx and HOPE MIAMI , May 13, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced signing of a definitive agreement to purchase the Kadima Neuropsychiatry Institute. Kadima is expected to serve as the clinical model for treatment offerings in HOPE-acquired clinics and is expected to continue its role as a leading investigative site for research into neuroplastic therapies including psychedelic medications, transcranial magnetic stimulation (TMS), and hyperbaric therapy. |
prnewswire.com |
2025-05-13 12:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Report First Quarter 2025 Financial Results on May 15, 2025 |
WILMINGTON, Del. , May 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its first quarter 2025 financial results after the market closes on Thursday, May 15, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. |
prnewswire.com |
2025-05-12 12:03:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Investor Event at Mar-A-Lago Club on May 8, 2025 |
MIAMI , May 6, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology-driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx" or the "Company") (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, today announced that it will host an investor event at the Mar-A-Lago Club in Palm Beach, Florida, on Thursday, May 8, 2025, at the invitation of club members. This discussion is being held to review previously-disclosed strategic initiatives across HOPE and NRx Pharmaceuticals, including expansion plans for the HOPE network of interventional psychiatry clinics and progress across the NRx clinical pipeline. |
prnewswire.com |
2025-05-06 12:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Patent Application for NRX-100, its Proprietary, Preservative Free Formulation of IV Ketamine |
Patent expected to be Orange Book listable, if granted NRX-100, preservative free, IV ketamine, is designed to avoid potential toxicity concerns linked to benzethonium chloride, used in currently available formulations of ketamine Filing strengthens NRx's leadership in advancing safe and effective treatments for suicidal depression WILMINGTON, Del. , May 5, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced the filing of a patent application for NRX-100, its preservative-free intravenous ketamine formulation for the treatment of suicidal depression. |
prnewswire.com |
2025-05-05 12:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc.to Participate in an H.C. Wainwright @ Home Fireside Discussion on Tuesday, April 22, 2025 |
WILMINGTON, Del. , April 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE," or the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, today announced that it will participate in an H.C. |
prnewswire.com |
2025-04-21 12:01:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of a Term Sheet for Strategic Investment from a Global Medical Device Manufacturer into HOPE |
Investment to support initiation of HOPE's network of clinics to treat suicidal depression and PTSD with ketamine, TMS and other modalities MIAMI , April 3, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP), today announced signing of a term sheet with a global medical device manufacturer, as anticipated in the Company's recently filed annual report. The investor shares HOPE's vision of providing comprehensive interventional psychiatry treatments to patients around the world. |
prnewswire.com |
2025-04-03 12:03:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Definitive Purchase Agreement with Dura Medical; Initial Acquisition for Planned International Network of Interventional Psychiatry Clinics |
Dura Medical, together with previously-announced acquisition of Neurospa TMS, will provide coverage throughout the West Coast of Florida Delivers a full range of precision psychiatry services for severe depression and PTSD, including Ketamine Therapy and Transcranial Magnetic Stimulation (TMS), to veteran and civilian patients Stephen Durand, founder of Dura, to serve as Director of Clinic Operations for HOPE in Florida MIAMI , March 31, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced signing of a definitive Agreement to acquire Dura Medical (Dura), per the previously announced non-binding Letter of Intent. Dura, together with the previously announced Neurospa network, are anticipated to provide a comprehensive service offering to patients on Florida's west coast. |
prnewswire.com |
2025-03-31 12:02:00 |
Czytaj oryginał (ang.) |
| Here's Why NRx Pharmaceuticals (NRXP) Is a Great 'Buy the Bottom' Stock Now |
NRx Pharmaceuticals (NRXP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term. |
zacks.com |
2025-03-27 12:55:35 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Letter of Intent with Neurospa TMS Holdings, LLC for Expansion of its Planned International Network of Interventional Psychiatry Clinics |
Neurospa currently operates six interventional psychiatry clinics on Florida's Gulf Coast HOPE to acquire majority interest in Neurospa for a combination of cash and equity Neurospa clinics deliver a full range of interventional psychiatry services, including Ketamine, Spravato ® and Transcranial Magnetic Stimulation (TMS) to patients with severe depression and related conditions Acquisition to be accretive to HOPE revenue projections for 2025 MIAMI , March 24, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), an interventional psychiatry network wholly owned by NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq:NRXP), today announced signing of a binding Letter of Intent to acquire a majority interest in Neurospa TMS Holdings, LLC, LLC (Neurospa). Neurospa operates six interventional psychiatry clinics on Florida's Gulf Coast and will constitute a key element of HOPE's Florida network going forward. |
prnewswire.com |
2025-03-24 10:02:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call Transcript |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Michael Abrams - Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Thomas Shrader - BTIG Vernon Bernardino - H.C. |
seekingalpha.com |
2025-03-17 12:50:56 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update |
Initiated filing of a New Drug Application ("NDA") to the FDA for NRX-100 (IV Ketamine) for the treatment of Suicidal Depression; planned filing of an NDA for Accelerated Approval under Breakthrough Designation and Priority Review of NRX-101 for the treatment of bipolar depression in people at risk of akathisia. Both have anticipated PDUFA dates prior to December 31, 2025 The Company has accepted non-binding potential terms from a commercial pharmaceutical company to license and distribute NRX-100, providing over $300 million in milestones plus tiered double-digit royalties based on net sales Retained a leading regulatory law firm to file a citizen's petition with the US Food and Drug Administration ("FDA") to remove benzethonium chloride – a toxic preservative -- from presentations of ketamine intended for intravenous use; planned 2Q25 filing of an Abbreviated New Drug Application ("ANDA") for the use of preservative-free ketamine in all current indications HOPE Therapeutics, a wholly owned subsidiary of NRx, signed non-binding letters of intent to acquire three precision psychiatry centers and is currently completing financial due diligence and definitive agreements. |
prnewswire.com |
2025-03-17 10:02:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 17, 2025 |
- Conference call to take place at 8:30am ET - WILMINGTON, Del. , March 12, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its fourth quarter and full year 2024 financial results before the market opens on Monday, March 17, 2025 via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. |
prnewswire.com |
2025-03-12 10:01:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals to Post Q4 Earnings: How to Play the Stock? |
NRXP is expected to provide updates on its pipeline candidates being developed for treating central nervous system disorders when it reports fourth-quarter earnings release. |
zacks.com |
2025-03-03 15:05:30 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. to Present at the Oppenheimer 35th Annual Healthcare Conference on February 12, 2025 |
• Management will also participate in the 2025 BIO CEO & Investor Conference and be available for one-on-one meetings in New York February 10 th-12th WILMINGTON, Del. , Feb. 6, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE"), a medical and technology driven company and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. announced today that Jonathan Javitt, MD, MPH, Founder, Chairman and Chief Executive Officer of NRx Pharmaceuticals will be presenting a Company update at the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11 th-12th. |
prnewswire.com |
2025-02-06 10:03:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Engage BTIG as Financial Advisor |
HOPE has announced plans to assemble a best-in-class global network of interventional psychiatry clinics combining ketamine treatment with transcranial magnetic stimulation, and digital therapeutics to treat severe depression and PTSD BTIG is a leading global financial services firm specializing in investment banking, institutional trading, research, and related brokerage services Advisory to include identification and evaluation of clinic partners and strategic assets and investment banking services in connection with financing initiatives to accelerate the Company's business plan MIAMI , Feb. 3, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced engagement of BTIG, a leading global financial services firm specializing in investment banking, institutional trading, research and related brokerage services. The scope of the engagement includes advisory and assistance in evaluating strategic and financing options available to the Company and identification, evaluation and negotiation of potential acquisition targets for the HOPE network of clinics, as well as equity and debt financing structures. |
prnewswire.com |
2025-02-03 10:59:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Execute Agreement for $27 Million Funding Transaction for HOPE Clinic Acquisition |
$25 million investment in HOPE to consist of Series A (non-dilutive to NRx shareholders) convertible into 1/3 of fully diluted HOPE equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions Initial funding of $2.0 million for purchase of NRx common stock anticipated to close on or before January 29, with the first tranche of $6.75 million of $25.0 million investment to be invested in HOPE Therapeutics, Inc. on or before February 7, 2025, and the balance of $18.25 million by April 1, 2025 Funds will be used in conjunction with anticipated bank financing to initiate nationwide rollup strategy of interventional psychiatry clinics, starting with Kadima Neuropsychiatry (La Jolla, CA) HOPE intends to initiate nationwide acquisition program in partnership with leading investment bank on or around February 1, 2025. MIAMI , Jan. 28, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc. ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced the signing and of a Stock Purchase Agreement ("SPA") with Smith & Sauer, LLC, as the first step in a $27.0 million financing to fund the planned acquisition of HOPE clinics. |
prnewswire.com |
2025-01-28 10:05:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt |
This financing is expected to support filing of New Drug Applications for NRX-100 (ketamine) and NRX-101, and to support launch of HOPE Therapeutics Investment consists of $3.5 million in above the market equity and $5.4 million in Senior Secured Notes; expected to fund current operations into 2026 WILMINGTON, Del. , Jan. 28, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", "NRx Pharmaceuticals" or the "Company"), a clinical-stage biopharmaceutical company, today announced that it has entered into a binding agreement for a registered direct offering of its common stock with expected gross proceeds of $3.5 million (the "Financing") with certain institutional investors. |
prnewswire.com |
2025-01-28 10:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement |
Company received written notice from the Nasdaq Listing Qualifications Staff stating that the Company regained compliance with the applicable Nasdaq minimum market value of listed securities continued listing requirement Nasdaq stated that the matter is now closed WILMINGTON, Del. , Jan. 21, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced that on January 17, 2025, it received written notice from the Nasdaq Listing Qualifications Staff (the "Staff") stating that the Company regained compliance with the market value of listed Securities ("MVLS") requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the "Rule") for continued listing on the Nasdaq Capital Market, and the matter is now closed. |
prnewswire.com |
2025-01-21 10:02:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces the Appointment of Michael Taylor to its Board of Directors and Appointment of Anita Nunes as Board Observer; Ms. Nunes to be Appointed Director of HOPE Therapeutics, Inc. |
WILMINGTON, Del. , Jan. 15, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., a development stage medical and technology driven company and wholly owned subsidiary of NRx, today announced the appointment of Mr. |
prnewswire.com |
2025-01-15 10:02:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Alert Investors to Sanjay Gupta/CNN Program on Ketamine, Featuring Kadima Neuropsychiatry Institute Founder Dr. David Feifel |
"'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta David Feifel MD PHD, Founder of Kadima, is a global thought leader in the interventional psychiatry field Kadima Neuropsychiatry Institute identified as planned HOPE Flagship Clinic pending acquisition closing Dr. Feifel is expected to join HOPE as Chief Medical Innovation Officer MIAMI , Jan. 14, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today alerted investors that Kadima Neuropsychiatry Institute's Founder David Feifel, MD PHD was featured as an expert in a program on ketamine entitled "'Special K': The Science & Stigma of Ketamine" on CNN, hosted by Dr. Sanjay Gupta. HOPE previously announced that Kadima is identified as the Company's planned flagship clinic acquisition, upon closing of the transaction. |
prnewswire.com |
2025-01-14 10:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces it has Filed an Application with NASDAQ to Uplist to the NASDAQ Global Market from the NASDAQ Capital Market |
Management believes uplisting has the potential to provide shareholders with improved liquidity Requires NRx Pharmaceuticals to meet certain listing requirements Company has advised NASDAQ that current shares outstanding is 15.7 million WILMINGTON, Del. , Jan. 13, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) ("NRx", the "Company"), a clinical-stage biopharmaceutical company, today announced it has applied to NASDAQ to uplist the Company's securities to the NASDAQ Global Market (NASDAQ GM). |
prnewswire.com |
2025-01-13 10:04:00 |
Czytaj oryginał (ang.) |
| Central Nervous System (CNS) Therapeutics Market Forecast (2025-2035) by Disease, Drug Class, Distribution Channel and Region |
Pfizer, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape Pfizer, Johnson & Johnson (Janssen Pharmaceuticals), Roche Holding, Novartis, and Eli Lilly & Company Dominate the Competitive Landscape |
globenewswire.com |
2025-01-08 12:20:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Dr. Jonathan Javitt and Dr. David Feifel to Present Keynote Address, Beyond Ketamine Monotherapy: Combined Interventional Treatment of Suicidal Depression and PTSD, at the 8th Annual Neuroscience Innovation Forum in San Francisco |
The Keynote Address, entitled " Beyond Ketamine: Combined Interventional Treatment of Suicidal Depression and PTSD ," will be presented at 10:30AM PT on Sunday January 12th, 2025 Prof. David Feifel MD PHD, designated Chief Medical Innovation Officer of HOPE and Founder of the Kadima Neuropsychiatry Institute, is an international thought leader in the interventional psychiatry space NRx Pharmaceuticals recently initiated filing of its NDA for NRX-100 (IV ketamine) for the treatment of suicidal depression Recent announcement of Kadima Neuropsychiatry Institute and Dura Medical as planned cornerstone acquisitions for HOPE Therapeutic's international network of interventional psychiatry clinics $27 Million in anticipated funding for HOPE Clinic acquisitions and pharmaceutical operations under a binding Term Sheet with an Institutional Investor MIAMI , Jan. 7, 2025 /PRNewswire/ -- HOPE Therapeutics™, Inc., ("HOPE"), a medical and technology driven company and wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx", and collectively with HOPE, the "Company") (Nasdaq:NRXP), today announced that Jonathan Javitt MD MPH, Founder and CEO of NRx and Co-CEO of HOPE, and Prof. |
prnewswire.com |
2025-01-07 10:07:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for January 6th |
NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024. |
zacks.com |
2025-01-06 13:35:43 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics™, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations |
Anticipated c apital from funds managed by Smith & Sauer to augment potential bank-financing for acquisition of HOPE Therapeutics clinics and support NRx Pharmaceutical operations. Purchase of $25 m illion in Series A Preferred Stock in HOPE Therapeutics (non-dilutive to NRXP shareholders) convertible into 1/3 of fully diluted HOPE Therapeutics equity, with a 15% current preferred dividend (non-callable for 2 years) for planned HOPE clinic acquisitions. |
prnewswire.com |
2025-01-06 12:16:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Announce Dura Medical as the Expected Initial Florida Acquisition for its Planned International Network of Interventional Psychiatry Clinics |
Dura Medical, with initial clinics in Naples and Fort Myers, to anchor the HOPE network in Florida Delivers a full range of precision psychiatry services, including Ketamine and Transcranial Magnetic Stimulation (TMS), to veteran and civilian residents of Florida Stephen Durand, founder of Dura, to serve as Director of Clinic Growth for HOPE in Florida Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI , Jan. 6, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced the planned acquisition of Dura Medical (Dura), under a non-binding Letter of Intent. Dura is expected to be the first Florida acquisition for HOPE and serve as a cornerstone for the Southeastern States. |
prnewswire.com |
2025-01-06 10:03:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for January 6th |
ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024. |
zacks.com |
2025-01-06 07:25:17 |
Czytaj oryginał (ang.) |
| Hope Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Kadima Neuropsychiatry Institute as the Expected First Acquisition for its International Network of Interventional Psychiatry Clinics |
Kadima Neuropsychiatry Institute in La Jolla, CA to serve as flagship for an international network of clinics dedicated to treating depression and PTSD Kadima's founder, David Feifel, MD, PhD, Professor Emeritus of Psychiatry at University of California San Diego, a pioneer in advanced interventional treatments for neuropsychiatric conditions such as depression and PTSD, to join Hope as Chief Medical Innovation Officer Kadima is a leading investigative site for CNS and psychedelic research, and has served as the lead site in nearly all major clinical trials in this area Acquisition expected to be immediately accretive to revenue and EBITDA for NRx MIAMI , Jan. 2, 2025 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced the planned acquisition of the Kadima Neuropsychiatry Institute (Kadima) of La Jolla, CA, per the previously announced Letter of Intent, for the HOPE network. Kadima is expected to serve as the flagship clinic for HOPE's planned international network of interventional psychiatry clinics, designed to provide advanced treatments for debilitating diseases such as depression, anxiety and PTSD. |
prnewswire.com |
2025-01-02 10:03:00 |
Czytaj oryginał (ang.) |
| Best Momentum Stocks to Buy for December 30th |
CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024. |
zacks.com |
2024-12-30 13:01:10 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Initial Section of U.S. New Drug Application to the FDA for NRX-100 (IV Ketamine) for the Treatment of Suicidal Depression |
Aiming to be the first FDA-approved medication to treat suicidal depression Designed to help address the needs of the more than 13 million Americans who seriously consider suicide each year (CDC) Completion of NDA filing expected in the first quarter of 2025 Company to participate in 1x1 meetings in San Francisco during the Annual J.P. Morgan Healthcare Conference on January 13-16, 2025, in San Francisco, CA. |
prnewswire.com |
2024-12-30 10:03:00 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 30th |
CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024. |
zacks.com |
2024-12-30 09:21:27 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 26th |
EGAN,ACMR, AVO, BB and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 26, 2024. |
zacks.com |
2024-12-26 08:00:26 |
Czytaj oryginał (ang.) |
| New Strong Buy Stocks for December 24th |
FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024. |
zacks.com |
2024-12-24 08:51:09 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why |
NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term. |
zacks.com |
2024-11-27 15:01:27 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals (NASDAQ: NRXP) Announces Participation in the NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference December 3-4, 2024 |
WILMINGTON, Del., Nov. 26, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that Dr. Jonathan Javitt, Chairman, CEO and Chief Scientist will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference at Florida Atlantic University, Executive Education Complex, in Boca Raton, FL. |
prnewswire.com |
2024-11-26 10:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals (NASDAQ:NRXP) Announces Publication of Paper Entitled "Quality Assurance of Depression Ratings in Psychiatric Clinical Trials" |
NRx-developed training and monitoring methodology in recently completed phase 2b/3 clinical trial of NRX-101 documents higher interrater reliability (IRR) on primary endpoint (MADRS depression scale) than previously reported industry standards Positive implications for conduct of future registration trials for NRX-101 and similar medications. Published in the peer reviewed American Journal of Clinical Psychopharmacology WILMINGTON, Del. |
prnewswire.com |
2024-11-25 10:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and Chief Scientist Richard Narido - Interim Chief Financial Officer and Treasurer Michael Abrams - Incoming Chief Financial Officer Conference Call Participants Jason Kolbert - D. Boral Capital Ed Woo - Ascendiant Vernon Bernardino - H.C. |
seekingalpha.com |
2024-11-18 21:51:23 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer |
Industry veteran with extensive experience in key areas of focus Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities WILMINGTON, Del., Nov. 18, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced it has appointed Michael Abrams as its permanent Chief Financial Officer. |
prnewswire.com |
2024-11-18 18:05:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update |
On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for Accelerated Approval in bipolar depression with suicidality or akathisia by year end 2024 with 2025 PDUFA date forecast. HOPE Therapeutics acquiring Interventional Psychiatry Clinics; key to developing a best-in-class network of care to prevent suicide, continues to expect first revenue by year-end 2024. |
prnewswire.com |
2024-11-14 18:05:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reschedules Conference Call to Discuss Third Quarter and Year to Date 2024 Financial Results to November 18, 2024 |
WILMINGTON, Del. , Nov. 13, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will reschedule its third quarter and year to date 2024 results conference call to Monday November 18, 2024 at 4:30pm ET, to accommodate any additional corporate news. |
prnewswire.com |
2024-11-13 10:03:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024 |
WILMINGTON, Del. , Nov. 7, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage biopharmaceutical company, today announced that it will release its third quarter and year to date 2024 financial results after the market closes on Thursday, November 14, 2024, via press release, which will be available on the Company's website at https://ir.nrxpharma.com/. |
prnewswire.com |
2024-11-07 18:06:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics |
The clinics are located in favorable locations, are revenue generating and EBITDA positive Clinics offer a comprehensive range of mental health services Acquisition is expected to be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 30, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. ("NRx") (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of its first Interventional Psychiatry Clinics in Florida. These clinics are seen as top performers and will form the Company's foundation for growth in Florida. |
prnewswire.com |
2024-10-30 09:47:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 |
MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc. |
prismmediawire.com |
2024-10-23 12:30:06 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024 |
MIAMI, Oct. 23, 2024 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc., a medical and technology driven company and wholly-owned subsidiary of NRx, today announced they will be featured as a participating in the ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York. The ThinkEquity Conference gathers institutional investors, corporate clients, and other industry professionals to highlight groundbreaking innovations and financial strategies. |
globenewswire.com |
2024-10-23 12:30:00 |
Czytaj oryginał (ang.) |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire a Premier West Coast Interventional Psychiatric Clinic |
Clinic to serve as the prototype for HOPE's network of Interventional Psychiatric Clinics Nationally recognized founder to become Chief Medical Innovation Officer of HOPE, in order to implement and evolve the Company's standard of care across the HOPE network Acquisition would be immediately accretive to revenue and EBITDA for HOPE and NRx MIAMI , Oct. 3, 2024 /PRNewswire/ -- HOPE Therapeutics, Inc., ("HOPE," the "Company"), a medical and technology driven company, and a wholly-owned subsidiary of NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), today announced signing a non-binding Letter of Intent (LOI) for acquisition of a premier West Coast Interventional Psychiatric Clinic. Importantly, as a component of the acquisition, the founder of the clinic, a pioneer and nationally recognized leader in the use of advanced treatments for treatment of CNS disorders, has agreed to join HOPE as Chief Medical Innovation Officer (CMIO). |
prnewswire.com |
2024-10-03 10:55:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months of Stability on the First Manufactured Commercial Scale Lot of NRX-100 (Ketamine) |
Stability milestone supports submission of FDA New Drug Application by NRx for the use of intravenous ketamine to treat Suicidal Depression Ketamine is currently used off-label for this indication. However, FDA approval is typically required for patients to obtain insurance reimbursement NRX-100 is the first preservative-free formulation of Ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use RADNOR, Pa. |
prnewswire.com |
2024-09-30 11:00:00 |
Czytaj oryginał (ang.) |
| NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Featured on Psychiatrist.com |
"How NRx Could Upend the Fight Against Depression and Suicide" RADNOR, Pa. , Sept. 11, 2024 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, ("NRx," the "Company"), today highlighted that the Company's pipeline products NRX-100 and NRX-101 were featured in an article published on Psychiatrist.com. |
prnewswire.com |
2024-09-11 11:55:00 |
Czytaj oryginał (ang.) |